Summary

Age-related macular degeneration (AMD) is the most frequent cause of blindness in industrialized countries. Multiple molecular pathways have been implicated in the pathogenesis of choroidal neovascularization (CNV). Currently, the treatment relies on neutralization of VEGF (Vascular Endothelial Growth Factor). However some patients have an incomplete response to anti-VEGF treatment. A recent study suggested the implication of the mineralocorticoid receptor pathway in the formation of CNV.

The study (of investigators) aim is to evaluate the concentration of metabolites of MR pathway in the blood and aqueous humor of patients with CNV and compared them with patients without CNV in order to increase our understanding of CNV pathogenesis and find potential biomarker of response to anti-VEGF treatment.

Study Name: Biomarkers Analysis of Mineralocorticoid Receptor Activation in the Serum and Ocular Fluid of Patients With Choroidal Neovascularization
Status: Not yet recruiting
Conditions: Choroidal Neovascularization, Mineralocorticoid Excess (aldosteronism)
Interventions: Blood and aqueous humor biomarker of treatment response
Locations: Institut National de la Santé Et de la Recherche Médicale, France
Study link: https://clinicaltrials.gov/ct2/show/NCT04439708

To search for other studies by topic, location, or status, go to our Clinical Studies page.

©2021 Primary Aldosteronism Foundation — All Rights Reserved

The Primary Aldosteronism Foundation is a registered 501(c)(3) public charity. Donations are tax deductible in the US.

©2021 Primary Aldosteronism Foundation

The Primary Aldosteronism Foundation is a registered 501(c)(3) public charity. Donations are tax deductible in the US.